Multiple Myeloma Clinical Trial
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Summary
Lenalidomide belongs to a group of drugs called immunomodulatory drugs (IMiD) that can modify or regulate the functioning of the immune system. It is an FDA approved drug for people with multiple myeloma. It is not currently approved for use in Chronic Lymphocytic Leukemia (CLL), but it does appear effective in CLL when used alone, and is being studied for use in combination with chemotherapy in this and other lymphomas and leukemias.
In this research study we are hoping to learn more about the effects of lenalidomide on CLL when given in combination with bendamustine and rituximab, which is a highly effective regimen for initial therapy of CLL/SLL. The investigators will be looking for the highest dose of lenalidomide that can be given safely, without causing any serious or unmanageable side effects.
Full Description
Subjects will receive lenalidomide, bendamustine and rituximab in cycles of 28 days (4 weeks). Lenalidomide will be administered orally once daily on days 8-21 of cycle 1 and on days 1-21 of all subsequent cycles. Bendamustine will be administered through a vein (IV infusion) on days 1 and 2 of each cycle. Rituximab will be administered as an IV infusion on day 1 of each cycle.
Subjects will receive routine blood tests and physical exam during each cycle. Tumor assessments by CT scan will be performed during cycles 2, 4, and 6.
Eligibility Criteria
Inclusion Criteria:
Diagnosed with B-cell CLL or SLL (chronic lymphocytic leukemia or small lymphocytic leukemia)
Life expectancy > 3 months
Organ and marrow function with protocol parameters
Able to take aspirin daily
Exclusion Criteria:
Age >80 years
Prior systemic therapy for CLL/SLL including chemotherapy or antibody therapy
Pregnant or breast-feeding
Serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing informed consent
Known hypersensitivity to thalidomide or lenalidomide
Prior use of lenalidomide
Concurrent use of other anti-cancer agents or treatments
HIV positive
Prior history of another malignancy unless disease free for at least 2 years
Uncontrolled intercurrent illness
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Boston Massachusetts, 02214, United States
Boston Massachusetts, 02215, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.